The startup is developing next-generation immunomodulators that enhance the immune response through targeted modulation of immune cell activity. These therapeutics aim to improve treatment outcomes for autoimmune diseases and cancer by precisely regulating immune system functions.
Funding
Funding not disclosed
Founders
Product
Problem
Existing cancer therapies often fail to achieve durable responses due to immunosuppression within the tumor microenvironment and a lack of effective T cell activation. This limits the efficacy of treatments and contributes to cancer recurrence and progression.
Solution
Sift Biosciences utilizes artificial intelligence and high-throughput cellular screening to discover and design immunotherapy boosters that enhance the effectiveness of existing cancer therapies. Their approach focuses on modulating the immune system to overcome immunosuppression and promote robust anti-tumor responses, ultimately aiming to improve patient survival rates. By identifying and developing targeted immunomodulators, Sift Biosciences seeks to supercharge the ability of current cancer treatments to eradicate tumors and prevent relapse.
Target Audience
The primary target audience includes pharmaceutical companies developing cancer therapies and clinical researchers focused on improving immunotherapy outcomes.
Features
- AI-driven platform for identifying novel immunotherapy targets
- High-throughput cellular screening to evaluate immunomodulatory activity
- Design of immunotherapy boosters to enhance T cell activation and infiltration
- Modulation of the tumor microenvironment to overcome immunosuppression